Regeneron preps for 2020 filing for new cholesterol drug aft...

Regeneron has announced data that could create a niche for its latest cholesterol drug evinacumab in a small group of patients who do not respond to the strongest available medicines.

First effective Ebola treatment a step closer after breakthr...

Clinical trials of four experimental treatments for Ebola in the Congo have been halted early after two of the drugs showed compelling benefits in a breakthrough against the deadly virus.

Almirall takes option on Dermira's eczema drug lebrikizumab

Spain’s Almirall has taken an option granting rights to develop and market Dermira’s eczema drug lebrikizumab in Europe, in a bid to take on Sanofi/Regeneron's recently approved Dupixent.

Sanofi/Regeneron asthma trial casts doubt on IL-33 class pro...

FDA approves Regeneron's Eylea for diabetic retinopathy

Regeneron’s Eylea injection has been approved in the US for diabetic retinopathy, to treat all stages of the disease and reduce the risk of blindness.

Sanofi claims EU okay for Dupixent in asthma

Sanofi and partner Regeneron have picked up an approval in Europe for Dupixent in asthma, unlocking an important new indication for the fast-growing biologic.